Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Fralick

Showing results (11-20 of 196) with videos related to

Pageof 20
Sort By:
Diabetologia|March 30, 2021
Correction to: The discovery of insulin in Toronto: beginning a 100 year journey of research and clinical achievementMichael Fralick, Bernard Zinman
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 4, 2014
Physician burnout: who will protect us from ourselves?Michael Fralick, Ken Flegel
NEJM Evidence|July 22, 2025
Which Patients with Heart Failure Benefit from an SGLT2 Inhibitor?Joseph Benjamen, Michael Fralick
BMJ (Clinical Research Ed.)|November 20, 2014
Authors' reply to Scheper and LijferingMichael Fralick, David N Juurlink
Diabetes, Obesity & Metabolism|January 17, 2020
A hypothesis for why sodium glucose co-transporter 2 inhibitors have been found to cause genital infection, but not urinary tract infectionMichael Fralick, Derek R MacFadden
JAMA|April 7, 2017
FDA Approval of Desmopressin for NocturiaMichael Fralick, Aaron S Kesselheim
JAMA|October 5, 2017
Low-Dose Desmopressin Nasal Spray and FDA Approval-ReplyMichael Fralick, Aaron S Kesselheim
NEJM Evidence|February 6, 2024
The Basics of Machine LearningMichael Fralick, Kieran R Campbell
Pharmacoepidemiology and Drug Safety|February 16, 2017
Periodic benefit-risk evaluation reports have substantial promise to guide patient care and should be made publicly availableMichael Fralick, Aaron S Kesselheim
NEJM Evidence|May 28, 2024
Heterogeneity of Treatment Effect - An Evolution in Subgroup AnalysisChristopher J Yarnell, Michael Fralick
Pageof 20

Showing results (11-20 of 196) with videos related to

Sort By:
Pageof 20
Diabetologia|March 30, 2021
Correction to: The discovery of insulin in Toronto: beginning a 100 year journey of research and clinical achievementMichael Fralick, Bernard Zinman
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 4, 2014
Physician burnout: who will protect us from ourselves?Michael Fralick, Ken Flegel
NEJM Evidence|July 22, 2025
Which Patients with Heart Failure Benefit from an SGLT2 Inhibitor?Joseph Benjamen, Michael Fralick
BMJ (Clinical Research Ed.)|November 20, 2014
Authors' reply to Scheper and LijferingMichael Fralick, David N Juurlink
Diabetes, Obesity & Metabolism|January 17, 2020
A hypothesis for why sodium glucose co-transporter 2 inhibitors have been found to cause genital infection, but not urinary tract infectionMichael Fralick, Derek R MacFadden
JAMA|April 7, 2017
FDA Approval of Desmopressin for NocturiaMichael Fralick, Aaron S Kesselheim
JAMA|October 5, 2017
Low-Dose Desmopressin Nasal Spray and FDA Approval-ReplyMichael Fralick, Aaron S Kesselheim
NEJM Evidence|February 6, 2024
The Basics of Machine LearningMichael Fralick, Kieran R Campbell
Pharmacoepidemiology and Drug Safety|February 16, 2017
Periodic benefit-risk evaluation reports have substantial promise to guide patient care and should be made publicly availableMichael Fralick, Aaron S Kesselheim
NEJM Evidence|May 28, 2024
Heterogeneity of Treatment Effect - An Evolution in Subgroup AnalysisChristopher J Yarnell, Michael Fralick
Pageof 20